Results 191 to 200 of about 470,342 (302)

Multi‐Method Geophysical Surveys Between and Around the Kerlescan and the Manio Megalithic Alignments in Carnac (Morbihan, France)

open access: yesArchaeological Prospection, EarlyView.
ABSTRACT The Carnac alignments in Morbihan (France) are among the most famous Neolithic sites of the world. Paradoxically, they have benefited little from a thorough renewal of archaeological data over the past century. There are many reasons for this, but it is mainly because the site has been regarded more as a monument to visit and protect than as ...
Guillaume Bruniaux   +6 more
wiley   +1 more source

The Layout and Size of an Early Pre‐Pottery Neolithic B Small Settlement Revealed by Geophysical Prospection at Harbetsuvan Tepesi in Southeastern Anatolia

open access: yesArchaeological Prospection, EarlyView.
ABSTRACT In Upper Mesopotamia, the transition from the Pre‐Pottery Neolithic A (PPNA) to Pre‐Pottery Neolithic B (PPNB) period, ca. 10 800–10 600 cal. BP, is marked by a series of changes in chipped stone industries, architectural forms, symbolic objects, regional distribution of settlements and long‐distance exchange networks among others.
Toshihiro Tada   +7 more
wiley   +1 more source

Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Evaluate performance of the Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator in rheumatoid arthritis (RA). Methods Patients with RA were matched up to 10 controls on age, sex, and enrollment year using National Veterans Health Administration, Medicare, and National Death Index data (2006–2020).
Tate M. Johnson   +13 more
wiley   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy